News

Panacea Biotec announced the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll� in sub-Saharan Africa (sSA) and to facilitate its broader global use. The four-year initiative is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), supported by the European Union and aligns with the EDCTP3 mission to combat Neglected Tropical Diseases (NTDs), including dengue fever, and seeks to reduce the disease burden across Africa. The DENSTAR project is coordinated by the �Sclavo Vaccines Association�, a non-profit organization based in Siena (Italy) devoted to support vaccine research and development in developing countries. The DENSTAR consortium unites 10 Partners from 9 countries across Europe, Africa, the United States, India and South Korea which comprises of universities, research organizations, a biotech company and a non profit organization, bringing together experts, researchers, regulators, healthcare practitioners. Panacea Biotec being the developer of DengiAll�, a tetravalent dengue vaccine targeting all four virus serotypes and currently in late-stage development in India, is a key partner of the DENSTAR consortium. This diverse and complementary consortium embodies a great public-private partnership, fully aligned with the DENSTAR project`s goal to promote broader use of DengiAll� in Africa and globally, contributing to equitable access to safe and effective dengue prevention tools.

Net profit of Panacea Biotec reported to Rs 0.52 crore in the quarter ended March 2026 as against net loss of Rs 1.89 crore during the previous quarter ended March 2025. Sales rose 25.82% to Rs 166.75 crore in the quarter ended March 2026 as against Rs 132.53 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 5.37 crore in the year ended March 2026 as against net loss of Rs 8.37 crore during the previous year ended March 2025. Sales rose 14.43% to Rs 639.77 crore in the year ended March 2026 as against Rs 559.09 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales166.75132.53 26 639.77559.09 14 OPM %1.54-20.28 --0.73-4.63 - PBDT3.92-19.33 LP 6.19-9.13 LP PBT-3.96-27.75 86 -26.87-43.94 39 NP0.52-1.89 LP -5.37-8.37 36 Powered by Capital Market - Live News

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Panacea Biotec announced that Mukul Gupta (DIN: 00254597), Independent Director of the Company has completed his second and final term of 5 (five) consecutive years as Independent Director on 31 March 2026 and accordingly he has ceased to be an Independent director of the Company.

Net profit of Panacea Biotec declined 11.95% to Rs 3.98 crore in the quarter ended December 2025 as against Rs 4.52 crore during the previous quarter ended December 2024. Sales rose 1.04% to Rs 165.19 crore in the quarter ended December 2025 as against Rs 163.49 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales165.19163.49 1 OPM %7.114.87 - PBDT12.1710.59 15 PBT3.721.61 131 NP3.984.52 -12 Powered by Capital Market - Live News